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Things are seldom what they seem, skim milk masquerades as
cream!
Duet – Little Buttercup and Captain, Act II, HMS Pinafore
The study of virus-associated human malignancy has provided
many important insights into the pathogenesis of cancer as well
as facilitating the development and testing of novel therapeutic
strategies relevant to the treatment of common cancers. Epstein-
Barr virus or EBV, as the ﬁrst oncogenic human virus to be iden-
tiﬁed, has been at the vanguard of these studies and even 40 years
after its discovery the virus continues to fascinate and surprise as it
yields up its secrets. The study of EBV intersects many disciplines
including cell biology, immunology, molecular biology and pathol-
ogy and this provides an important advantage in tackling the
complexity of the tumorigenic process. The virus also provides a
useful paradigm for the beneﬁts and challenges associated with
the impact of having a complete DNA sequence on our under-
standing of human disease. The full DNA sequence of the EBV
genome, some 172 kilobases, was published in 1984 thus we are
almost 20 years into the post-genomic era but the ‘big questions’
relating to such areas as the nature of virus persistence and replica-
tion in vivo and the precise contribution of the virus to the
oncogenic process are only just beginning to be unravelled. This
is a salutary lesson that highlights the need for restraint in
propounding the immediate beneﬁts of the human genome
sequence to the elucidation of disease processes and the develop-
ment of new treatments. Nevertheless EBV has come a long way
and this slender volume edited by Kenzo Takada nicely highlights
the current state of the ﬁeld and sets the scene for the challenges
ahead.
‘Epstein-Barr Virus and Human Disease’ is a selective collection
of reviews from experts in Japan and the United States covering a
range of topics. While considering detailed aspects of EBV biology
such as virus replication and the function of EBV-encoded glyco-
proteins, some key fundamental features of the virus like the
function of the latent membrane proteins (LMP1 and LMP2) or
the latest theories on the nature and site of EBV persistence are
not covered. This reﬂects the interests of the various authors and
with nine of the 14 chapters being provided by Japanese researchers
the volume is naturally biased towards certain topics at the expense
of others. This is best exempliﬁed in Section II which covers EBV-
associated malignancies and provides two chapters on those
tumours which are of particularly interest and importance in Japan
(namely gastric adenocarcinoma and nasal lymphoma) but rela-
tively rare in the West. The other review on AIDS lymphoma in
relation to both EBV and HHV8 seems a little out of place and
some consideration of the evidence and recent work implicating
EBV in the aetiology of Hodgkin’s disease or nasopharyngeal carci-
noma (NPC) may have been more appropriate. These minor
deﬁciencies are more than compensated by the editor’s own contri-
bution and that of Jeff Sample’s group describing their studies
using the Burkitt lymphoma (BL) cell line, Akata, to examine the
role of EBV in the pathogenesis of BL. Takada was the ﬁrst to
describe the ability of EBV-positive Akata BL cells to lose the virus
in culture with consequent loss of the transformed phenotype and
his chapter summarises these studies. This system provides a valu-
able tool for dissecting the role of individual EBV-encoded latent
genes in the oncogenic process and for generating recombinant
forms of the virus. The use of this approach to examine the impact
of EBV infection on cell growth and on c-myc expression, a central
player in the pathogenesis of BL, is reviewed by Ruf et al. Another
important contribution from Takada’s group has been the use of
recombinant drug-resistant forms of EBV to infect epithelial cells
and thus Imai et al provide a superb review of this area highlight-
ing the association of the virus with NPC and other carcinomas
and examining over 20 years’ worth of in vitro studies attempting
to elucidate the nature of the virus-epithelial cell interaction.
The volume also contains a section on the molecular mechan-
isms of maintenance and disruption of virus latency. Two
reviews deal with the factors governing the extrachromosomal
maintenance and replication of the circular (episomal) EBV
genome. Here the interaction of the EBNA1 protein with the latent
viral replication origin, oriP, is described and the possible role of
cellular licensing factors in controlling replication of the EBV
episome is considered. Two chapters cover the other aspect of virus
replication, that is the activation of the EBV lytic cycle which
results in the production of progeny virus. Tsurimi examines the
role of various viral proteins in this complex process and provides
a model for the EBV replication fork whereas Fujiwara describes
his work on the possible inﬂuence of the EBNA2 protein on lytic
cycle induction. Lindsey Hutt-Fletcher’s chapter on the two major
EBV glycoprotein complexes is an important reminder of the criti-
cal functions of these membrane proteins in relation to EBV
replication and tropism and how these might impact on EBV
pathogenesis. The ﬁnal section of the book deals with animal
models and therapeutic approaches. Fred Wang reviews the EBV-
like herpesviruses infecting Old World primates and describes the
similarities, at both the molecular and biological level, of these
so-called lymphocryptoviruses (LCVs). Rhesus LCV is a particularly
good model for EBV in terms of tumour association, in vitro B cell
transformation and the natural history of infection and thus
provides a valuable experimental model to study key aspects of
EBV pathogenesis such as the role of latent genes in acute and
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associated tumorigenesis. Finally, Clio Rooney and co-workers
consider the use of EBV-speciﬁc cytotoxic T lymphocytes for the
treatment of virus-associated tumours. This group has pioneered
this form of adoptive immunotherapy for the treatment of EBV-
induced lymphoproliferative disease and the chapter reviews their
experience with a comprehensive assessment of the ‘pros and cons’
of this therapy. The possibility of using this approach for the treat-
ment of other EBV-associated tumours such as Hodgkin’s disease is
also discussed.
‘Things are seldom what they seem’ when it comes to studying
virus-associated human tumours. There are many challenges and
paradoxes. For instance, EBV is probably one of the most common
viral infections throughout the world but only a small proportion
of infected individuals develop tumours and these differ dependent
on where you reside. This highlights the complexity of oncogenesis
and the fact that whilst EBV may be essential in this process other
factors working in concert with virus infection are required to fully
transform a normal cell. For many years EBV-induced transforma-
tion of B lymphocytes in culture was considered to be a model for
virus-associated cancers until it was discovered that EBV adopts
distinct patterns of latent gene expression in different tumours
and that in certain situations such as BL the virus-encoded proteins
considered to have oncogenic activity are not expressed! These are
important points for post-graduate students and post-doctoral
research fellows to appreciate which may not be clear from a read-
ing of this volume. However, the book provides a useful but
selective snap shot of the current state of play contrasting our
detailed knowledge of certain molecular aspects of EBV biology
with almost complete ignorance of fundamentally important
processes such as the role of EBV in the pathogenesis of NPC or
the contribution of epithelial cell infection to virus persistence
and replication. The book also highlights the value of new
approaches, particularly the ability to generate EBV recombinants,
as well as illustrating how new treatments can be developed with-
out a full understanding of the disease process. There’s much still
to do and, with an increasing number of viruses being implicated
in the development of human cancer, EBV stands as a paradigm
for both tumour virology and for the challenges of the post-geno-
mic era.
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